With Cerezyme, Genzyme began by figuring out what kind of doctors patients with Gaucher disease visit.

FORBES: Magazine Article

Cerezyme, Genzyme's first drug, treats a disease that afflicts fewer than 10, 000 patients globally.

FORBES: Magazine Article

In 1991, when it first launched Cerezyme for Gaucher disease, which afflicts a mere 6, 000 people worldwide, many thought sales wouldn't amount to much.

FORBES: Magazine Article

Gene therapy, if it works, is likely to become the ideal treatment for exactly the kinds of problems that Genzyme's drugs, like Cerezyme, treat.

FORBES: Genzyme Takes Gamble On Gene Therapy

Some big-selling biotech drugs are proteins themselves: Amgen's (nyse: AMGN - news - people) Epogen, Immunex's (nasdaq: IMNX - news - people) Enbrel and Genzyme's (nasdaq: GENZ - news - people) Cerezyme, for example.

FORBES: Rosetta Inpharmatics Riding The Gene Wave